Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial

Next Previous
Trial Profile

Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Famitinib (Primary)
  • Indications Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms basket
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 30 Jun 2022 Planned End Date changed from 1 Jun 2021 to 1 Dec 2022.
  • 30 Jun 2022 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2022.
  • 16 Aug 2021 Results (n=38; between Feb 20, 2019 and Apr 28, 2020) assessing efficacy and safety of camrelizumab plus famitinib in the advanced or metastatic renal cell carcinoma cohort, published in the Clinical Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top